Global Innovative Platforms (GIPL) Capital Expenditures (2026)
Global Innovative Platforms' (GIPL) quarterly Capital Expenditures came in at $55116.0 in Q2 2026.
Powered by 
Analysis
Global Innovative Platforms (GIPL) Capital Expenditures (2026) Analysis & Trends
Global Innovative Platforms has disclosed Capital Expenditures across 1 years of filings, most recently posting $55116.0 for Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Idexx Laboratories | 40.69 Bn | 40.49 Bn | 779.09 Mn | 24.65 Mn |
| 2 | Zoetis | 30.63 Bn | 28.95 Bn | 1.05 Bn | 117.00 Mn |
| 3 | Elanco Animal Health | 11.77 Bn | 11.24 Bn | 798.00 Mn | 33.00 Mn |
| 4 | Phibro Animal Health | 1.49 Bn | 1.41 Bn | 134.40 Mn | 18.87 Mn |
| 5 | Immucell | 90.19 Mn | 81.33 Mn | 2.44 Mn | - |
| 6 | Zhengye Biotechnology Holding | 76.23 Mn | 69.14 Mn | - | - |
| 7 | Global Innovative Platforms | 24.88 Mn | 24.63 Mn | - | 55,116.00 |